Onconic Therapeutics

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 47.0B cash and cash equivalents at fiscal year-end 2025
• • Net debt KRW -47.0B (net cash position), no borrowings reported at FY2025-end

Business Overview

• • Small molecule drug company focused on acid-related diseases and synthetic lethality oncology, generating 100% revenue from pharmaceuticals
• • Zastaprazan (P-CAB) launched Oct 1, 2024, approved as Korea’s 37th domestic new drug with additional gastric ulcer indication approval in Jun 2025

Management Discussion & Analysis

• • Revenue KRW 53.39B (+259.8% YoY); Operating profit KRW 12.62B (turnaround from -KRW 4.80B); Net income KRW 15.78B (turnaround from -KRW 8.09B)
• • Profit increase driven by milestone payments and contract revenues; management notes pipeline entering Phase 2 clinical trials raising R&D costs

What are the latest Onconic Therapeutics DART filings in 2026?

Onconic Therapeutics (KRX code 476060) has filed an annual report on March 13, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Onconic Therapeutics file its most recent annual report?

Onconic Therapeutics filed its most recent annual report on March 13, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Onconic Therapeutics's KRX stock code?

Onconic Therapeutics's KRX stock code is 476060. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 476060 to look up all Onconic Therapeutics disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Onconic Therapeutics file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Onconic Therapeutics.

Where can I find Onconic Therapeutics financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Onconic Therapeutics annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.